Acandis has announced the completion of its merger with Angionautix—a Spain- and Latin America-based neurovascular distribution specialist. Angionautix will continue to operate under its own brand and culture, with its founding team remaining in place to lead the next chapter of the company’s growth.
A recent press release notes that joining forces with Acandis opens a “new frontier” for Angionautix. With access to a broader product portfolio, deeper research and development (R&D) capabilities, and a European operational backbone, the Angionautix team will be “better equipped than ever” to serve its markets and its patients.
Additionally, for Acandis, Angionautix unlocks a “meaningful and immediate presence” in some of the world’s most dynamic markets for neurovascular care, the release adds.
“Today marks an important milestone in Acandis’s journey to become a leading global neurovascular company,” said Acandis chief executive officer (CEO) Andreas Schüssler and Acandis president Kirsi Schüssler. “What impressed us from the very beginning was the exceptional business that the Angionautix team has built, their strong clinical relationships, deep market expertise and unwavering commitment to patient care. We share the same passion for innovation, excellence and supporting physicians in delivering life-saving treatments. Together, we are creating a stronger platform that will expand access to advanced neurovascular technologies across Spain, Portugal, Chile and Mexico. We are delighted to welcome the entire Angionautix team to the Acandis family and look forward to building the future together.”
“We are proud of what we have done so far and the great team we created, but our very demanding business requires a continuous will to innovate and adapt our organisations to the new challenges ahead,” commented Alberto Pérez-Rosado, CEO of Angionautix. “This integration with Acandis, the most cutting-edge neurovascular manufacturer, opens a bright future for us. We are now one team focused on serving our customers in all the steps from R&D to clinical practice.”
Lauxera Capital Partners—Acandis’s investor and strategic partner—has supported this transaction as “a key step in building a truly global neurovascular platform”.
“Angionautix was the perfect match for Acandis’s sense of excellence, professionalism and passion for delivering critical care to patients globally. We are thrilled to partner with them and to strengthen our direct presence in key markets,” added Edoardo Fracchia, partner at Lauxera Capital Partners.
